Chemomab Therapeutics Ltd.
CMMB
$2.49
-$0.04-1.58%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 975.00K | 802.00K | 874.00K | 840.00K | 2.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.26M | 3.21M | 3.71M | 3.77M | 9.05M |
| Operating Income | -2.26M | -3.21M | -3.71M | -3.77M | -9.05M |
| Income Before Tax | -2.06M | -2.96M | -3.48M | -3.63M | -8.73M |
| Income Tax Expenses | -- | -- | -- | -- | 21.00K |
| Earnings from Continuing Operations | -2.06M | -2.96M | -3.48M | -3.63M | -8.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.06M | -2.96M | -3.48M | -3.63M | -8.75M |
| EBIT | -2.26M | -3.21M | -3.71M | -3.77M | -9.05M |
| EBITDA | -2.25M | -3.20M | -3.69M | -3.75M | -9.03M |
| EPS Basic | -28.40 | -50.28 | -63.58 | -81.23 | -15.84 |
| Normalized Basic EPS | -0.22 | -0.39 | -- | -0.63 | -0.49 |
| EPS Diluted | -28.40 | -50.28 | -63.58 | -81.23 | -15.84 |
| Normalized Diluted EPS | -0.22 | -0.39 | -- | -0.63 | -0.49 |
| Average Basic Shares Outstanding | 5.79M | 4.71M | 4.38M | 3.58M | 11.05M |
| Average Diluted Shares Outstanding | 72.40K | 58.90K | 54.70K | 44.70K | 552.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |